3 Results for:
-
Bromodomaine Inhibitors to Target Therapy-Resistant Cancer
The Problem:Glioblastoma multiforme (GBM) is the most common and the most aggressive malignant brain tumor in adults, having an overall incidence of approximately three new cases per 100,000 persons per year. Presently, GBM is highly lethal, with a median survival of 14 to15 months after diagnosis and no effective treatment for a significant long-term... (read more) -
Inhibitors of Autotaxin for Drug Resistant Cancer Stem Cells and Fibrotic Diseases
The Technology Solution: Autotaxin (ATX, NPP2) is a member of the nucleotide pyrophosphate phosphodiesterase enzyme family. ATX catalyzes the hydrolytic cleavage of lysophosphatidylcholine (LPC) that leads to the generation of the growth factor-like lipid mediator lysophosphatidic acid (LPA). ATX stimulates the motility of tumor cells and has angiogenic... (read more) -
Small Molecule Inhibitors of Autotaxin for Cancer Therapeutics
Technical Field:Cancer invasion and metastasis, lymphocyte recirculation, macular angiogenesis, allodynia and neuropathic pain, inflammation, cholestasis-associated pruritus.The Technology: Autotaxin (ATX, NPP2) is a member of the nucleotide pyrophosphate phosphodiesterase enzyme family. ATX catalyzes the hydrolytic cleavage of lysophosphatidylcholine... (read more)